Related Experiment Video
Updated: Jun 23, 2026

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice
Published on: March 24, 2017
Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple
F Bernal1, B Elias, H P Hartung
1Department of Neurology, Research Group for Clinical and Experimental Neuroimmunology, Heinrich-Heine-University, Düsseldorf, Germany.
Background:
Matrix metalloproteinases (MMPs) represent a large family of proteolytic enzymes, with some members being implicated in the immunopathogenesis of multiple sclerosis (MS). Interferon (IFN)-beta is one of the current mainstays in MS therapy and known to downregulate the expression of MMP-9. However, only sparse information is available on the effects of IFN-beta on the other 20 members of the MMP family.
Methods:
This is a longitudinal analysis on the RNA expression pattern of all known MMPs and their endogenous inhibitors before and after 1 and 6 months of IFN-beta therapy. RNA expression levels were assessed in peripheral venous blood cells from 14 MS patients and 8 matched controls by real time-PCR.
Results:
RNA expression levels before treatment differed in part in MS patients compared to healthy controls (MMP-9, MMP-14, MMP-19, TIMP-1, TIMP-2). Some of the MMPs responded to therapy specifically (MMP-8, MMP-9, MMP-19), whereas others remained unchanged over time.
Conclusions:
These data suggest that MMPs may differ in their expression levels in MS patients and that this group of enzymes is differentially regulated during the treatment with IFN-beta in MS for at least 6 months.
Insights
Interferon-beta therapy differentially regulates matrix metalloproteinases (MMPs) in multiple sclerosis (MS) patients. This study reveals specific MMPs are altered during treatment, suggesting a role for MMPs in MS immunopathogenesis.
Area of Science:
- Neuroimmunology
- Enzymology
- Pharmacogenomics
Background:
- Matrix metalloproteinases (MMPs) are implicated in multiple sclerosis (MS) immunopathogenesis.
- Interferon-beta (IFN-beta) is a key therapy for MS, known to affect MMP-9 expression.
- Limited data exists on IFN-beta's impact on other MMP family members.
Purpose of the Study:
- To investigate the longitudinal effects of IFN-beta therapy on the expression of all known MMPs and their inhibitors in MS patients.
- To compare MMP expression patterns in MS patients versus healthy controls.
Main Methods:
- Longitudinal analysis of RNA expression in peripheral blood cells from 14 MS patients and 8 controls.
- Real-time PCR used to assess expression of all MMPs and endogenous inhibitors before and after 1 and 6 months of IFN-beta therapy.
Main Results:
- Significant differences in RNA expression levels of MMP-9, MMP-14, MMP-19, TIMP-1, and TIMP-2 were observed between MS patients and controls prior to treatment.
- MMP-8, MMP-9, and MMP-19 showed specific responses to IFN-beta therapy.
- Other MMPs exhibited unchanged expression levels over the 6-month treatment period.
Conclusions:
- MMP expression levels may vary in individuals with MS.
- IFN-beta therapy differentially regulates specific MMPs in MS patients over a 6-month period.
- These findings highlight the complex role of MMPs in MS and their modulation by IFN-beta treatment.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Role of Matrix Metalloproteases in Degradation of ECM
A...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
